We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 98.27%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNX
26
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$29.7M 0.24%
3,150,808
– –
MRUS
27
DELISTED
Merus
MRUS
$28.3M 0.23%
1,160,014
– –
ACGN
28
DELISTED
Aceragen Inc
ACGN
$25.4M 0.21%
75,712
+105
+0.1% +$25.3K
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$23.6M 0.19%
4,530,901
+475,025
+12% +$1.91M
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$22.4M 0.18%
259,894
– –
XNCR icon
31
Xencor
XNCR
$2.07B
$20.9M 0.17%
872,072
– –
HALO icon
32
Halozyme
HALO
$12.3B
$18M 0.15%
1,391,507
– –
NDRM
33
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$15.2M 0.12%
571,667
– –
NTLA icon
34
Intellia Therapeutics
NTLA
$1.8B
$15M 0.12%
1,062,120
– –
SAGE
35
DELISTED
Sage Therapeutics
SAGE
$14.8M 0.12%
208,328
– –
AIMT
36
DELISTED
Aimmune Therapeutics
AIMT
$14.6M 0.12%
673,908
– –
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$14.2M 0.12%
1,585,913
-1,000,000
-39% -$10.6M
DERM
38
DELISTED
Dermira, Inc.
DERM
$14.2M 0.12%
415,448
+89,020
+27% +$2.87M
AERI
39
DELISTED
Aerie Pharmaceuticals
AERI
$13.6M 0.11%
299,356
– –
FOMX
40
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$12.2M 0.1%
2,466,702
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.8M 0.1%
2,269,198
– –
IMGN
42
DELISTED
Immunogen Inc
IMGN
$11.7M 0.1%
3,015,353
– –
LJPC
43
DELISTED
La Jolla Pharmaceutical Company
LJPC
$11.3M 0.09%
379,134
+365,388
+2,658% +$9.33M
CPRX
44
DELISTED
Catalyst Pharmaceutical
CPRX
$9.95M 0.08%
5,102,153
– –
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.9M 0.08%
609,166
– –
ALKS icon
46
Alkermes
ALKS
$8.11B
$8.79M 0.07%
150,251
– –
ABEO icon
47
Abeona Therapeutics
ABEO
$348M
$8.42M 0.07%
67,375
– –
RIGL icon
48
Rigel Pharmaceuticals
RIGL
$857M
$8.34M 0.07%
251,888
+50,000
+25% +$1.27M
ACHN
49
DELISTED
Achillion Pharmaceuticals
ACHN
$7.82M 0.06%
1,856,637
– –
LGND icon
50
Ligand Pharmaceuticals
LGND
$5.71B
$7.77M 0.06%
117,638
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2017 Portfolio in Review

As of Q1 2017, Julian Baker held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 88% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Julian Baker's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Julian Baker added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Julian Baker's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Julian Baker fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Julian Baker's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Julian Baker opened 4 new positions and closed 18 in Q1 2017.
  • Julian Baker's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.